Newsfeeds - Spark Newswire

2 minute read

General

Pulse8 Receives NCQA Measure Certification For HEDIS MY2022 For Qualit8, A Veradigm Network Solution

Today, 1:37 PM

Pulse8 is thrilled to announce that Qualit8, a Veradigm Network Solution, has achieved MY2022 Measure Certification from the National Committee for Quality Assurance (NCQA) for the third consecutive year.

MDRX

14 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For July 12, 2022

By Benzinga Insights

Today, 1:37 PM

Upgrades

AGRI

1 minute read

Goldman Sachs Initiates Coverage On Allscripts Healthcare with Neutral Rating, Announces Price Target of $21

By Benzinga Newsdesk

Today, 1:37 PM

Goldman Sachs analyst Cindy Motz initiates coverage on Allscripts Healthcare (NASDAQ:MDRX) with a Neutral rating and announces Price Target of $21.

MDRX

1 minute read

Piper Sandler Maintains Neutral on Allscripts Healthcare, Lowers Price Target to $17

By Benzinga Newsdesk

Today, 1:37 PM

Piper Sandler analyst Jeff Garro maintains Allscripts Healthcare (NASDAQ:MDRX) with a Neutral and lowers the price target from $19 to $17.

MDRX

1 minute read

Piper Sandler Maintains Neutral on Allscripts Healthcare, Lowers Price Target to $19

By Benzinga Newsdesk

Today, 1:37 PM

Piper Sandler analyst Jeff Garro maintains Allscripts Healthcare (NASDAQ:MDRX) with a Neutral and lowers the price target from $22 to $19.

MDRX

30 minute read

Earnings Scheduled For May 5, 2022

By Benzinga Insights

Today, 1:37 PM

Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.

AAOI

1 minute read

Analyst Ratings

Where Allscripts Healthcare Stands With Analysts

By Benzinga Insights

Today, 1:37 PM

Allscripts Healthcare (NASDAQ:MDRX) has observed the following analyst ratings within the last quarter:

MDRX

1 minute read

Piper Sandler Maintains Neutral on Allscripts Healthcare, Raises Price Target to $22

By Benzinga Newsdesk

Today, 1:37 PM

Piper Sandler analyst Jeff Garro maintains Allscripts Healthcare (NASDAQ:MDRX) with a Neutral and raises the price target from $19 to $22.

MDRX

1 minute read

Deutsche Bank Upgrades Allscripts Healthcare to Buy, Raises Price Target to $26

By Benzinga Newsdesk

Today, 1:37 PM

Deutsche Bank analyst George Hill upgrades Allscripts Healthcare (NASDAQ:MDRX) from Hold to Buy and raises the price target from $20 to $26.

MDRX

2 minute read

Allscripts Reports Sale Of Net Assets Of Its Hospitals, Large Physician Practices Business Segment To Constellation Software

By Benzinga Newsdesk

Today, 1:37 PM

Allscripts Healthcare Solutions (NASDAQ:MDRX) ("Allscripts") announced today that it has reached an agreement with Constellation Software Inc. (TSX:CSU), through its wholly-owned subsidiary N. Harris Computer

MDRX